Journal of Clinical Oncology

Reply to: Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging

F Floris J. Pos (Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium) K Karolína Menne Guricová (Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium) J Jochem R.N. van der Voort van der Zyp (Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium) R Robert J. Smeenk (Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium) U Uulke A. van der Heide (Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium) K Karin Haustermans C Cédric Draulans (Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium)
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 44, Issue 10
Published April 01, 2026
Pages 946-947
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (7)

F

Floris J. Pos

Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium

K

Karolína Menne Guricová

Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium

J

Jochem R.N. van der Voort van der Zyp

Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium

R

Robert J. Smeenk

Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium

U

Uulke A. van der Heide

Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium

K

Karin Haustermans

C

Cédric Draulans

Floris J. Pos, MD, PhD, and Karolína Menne Guricová, MSc, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands; Jochem R.N. van der Voort van der Zyp, MD, PhD, Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands; Robert J. Smeenk, MD, PhD, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands; Uulke A. van der Heide, PhD, Department of Radiation Oncology, Netherlands Cancer Institute (NKI-AVL), Amsterdam, the Netherlands;Karin Haustermans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium, Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium; and Cédric Draulans, MD, PhD, Department of Oncology, KU Leuven, Leuven, Belgium

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001